Related Experiment Video
Updated: Mar 7, 2026
11:42
Induction of Mesenchymal-Epithelial Transitions in Sarcoma Cells
Published on: April 7, 2017
9.9K
Metastatic biomarkers in synovial sarcoma
Rosalia de Necochea-Campion1, Lee M Zuckerman2, Hamid R Mirshahidi3
1Biospecimen Laboratory, Loma Linda University Cancer Center, Loma Linda University School of Medicine, 11175 Campus Street, Chan Shun Pavilion 11017, Loma Linda, CA 92354 USA.
Biomarker Research
|February 14, 2017
Summary
Synovial sarcoma (SS) is a rare, aggressive cancer. Understanding SS invasion and metastasis is crucial for developing targeted therapies to improve patient outcomes.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Synovial sarcoma (SS) is an aggressive soft tissue sarcoma (STS).
- Metastasis commonly occurs in the lungs and lymph nodes, leading to a poor prognosis.
- Current treatments include surgery, chemotherapy, and radiation, but are insufficient for metastatic disease.
Purpose of the Study:
- To investigate the poorly understood biology of sarcoma invasion and metastasis.
- To identify potential diagnostic markers and therapeutic targets for synovial sarcoma.
- To explore the impact of SYT-SSX gene fusion and other biomarkers on SS behavior.
Main Methods:
- Review of existing literature on synovial sarcoma.
- Analysis of chromosomal translocations, specifically SYT-SSX gene fusion.
- Investigation of multiple biomarkers associated with SS.
Main Results:
- The SYT-SSX gene fusion is a known diagnostic marker for SS.
- The full impact of the SYT-SSX fusion on SS biology remains unclear.
- Several biomarkers are associated with SS and are under investigation for their roles.
Conclusions:
- Further research is essential to develop improved diagnostic tools and understand SS tumor behavior.
- Targeted therapies aimed at reducing metastasis are needed to significantly improve patient prognosis.
- Elucidating the mechanisms of SS invasion and metastasis is critical for advancing treatment strategies.
